Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study

Yutaka Imai; Kei Kamide; Kei Asayama; Tomohiro Katsuya; Takayoshi Ohkubo; Takuo Hirose; Ryusuke Inoue; Hirohito Metoki; Masahiro Kikuya; Taku Obara; Hironori Hanada; Lutgarde Thijs; Tatiana Kuznetsova; Yuichi Noguchi; Ken Sugimoto; Mitsuru Ohishi; Shigeto Morimoto; Takeshi Nakahashi; Shin Takiuchi; Toshihiko Ishimitsu; Takuya Tsuchihashi; Masayoshi Soma; Jitsuo Higaki; Hideo Matsuura; Tatsuo Shinagawa; Toshiyuki Sasaguri; Tetsuro Miki; Kazuo Takeda; Kazuaki Shimamoto; Michio Ueno; Naohisa Hosomi; Jyouji Kato; Norio Komai; Shunichi Kojima; Kazuhiro Sase; Toshiyuki Miyata; Hitonobu Tomoike; Yuhei Kawano; Toshio Ogihara; Hiromi Rakugi; Jan A. Staessen

doi:10.2217/PGS.13.161

Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study

Yutaka Imai, Kei Kamide, Kei Asayama, Tomohiro Katsuya, Takayoshi Ohkubo, Takuo Hirose, Ryusuke Inoue, Hirohito Metoki, Masahiro Kikuya, Taku Obara, Hironori Hanada, Lutgarde Thijs, Tatiana Kuznetsova, Yuichi Noguchi, Ken Sugimoto, Mitsuru Ohishi, Shigeto Morimoto, Takeshi Nakahashi, Shin Takiuchi, Toshihiko IshimitsuTakuya Tsuchihashi, Masayoshi Soma, Jitsuo Higaki, Hideo Matsuura, Tatsuo Shinagawa, Toshiyuki Sasaguri, Tetsuro Miki, Kazuo Takeda, Kazuaki Shimamoto, Michio Ueno, Naohisa Hosomi, Jyouji Kato, Norio Komai, Shunichi Kojima, Kazuhiro Sase, Toshiyuki Miyata, Hitonobu Tomoike, Yuhei Kawano, Toshio Ogihara, Hiromi Rakugi, Jan A. Staessen

Science for Biological Information

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). Methods: We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10-4, we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine. Results: SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication. Conclusion: Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.

Original language	English
Pages (from-to)	1709-1721
Number of pages	13
Journal	Pharmacogenomics
Volume	14
Issue number	14
DOIs	https://doi.org/10.2217/PGS.13.161
Publication status	Published - Nov 2013

All Science Journal Classification (ASJC) codes

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/PGS.13.161

Cite this

Imai, Y., Kamide, K., Asayama, K., Katsuya, T., Ohkubo, T., Hirose, T., Inoue, R., Metoki, H., Kikuya, M., Obara, T., Hanada, H., Thijs, L., Kuznetsova, T., Noguchi, Y., Sugimoto, K., Ohishi, M., Morimoto, S., Nakahashi, T., Takiuchi, S., ... Staessen, J. A. (2013). Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study. Pharmacogenomics, 14(14), 1709-1721. https://doi.org/10.2217/PGS.13.161

Imai, Y, Kamide, K, Asayama, K, Katsuya, T, Ohkubo, T, Hirose, T, Inoue, R, Metoki, H, Kikuya, M, Obara, T, Hanada, H, Thijs, L, Kuznetsova, T, Noguchi, Y, Sugimoto, K, Ohishi, M, Morimoto, S, Nakahashi, T, Takiuchi, S, Ishimitsu, T, Tsuchihashi, T, Soma, M, Higaki, J, Matsuura, H, Shinagawa, T, Sasaguri, T, Miki, T, Takeda, K, Shimamoto, K, Ueno, M, Hosomi, N, Kato, J, Komai, N, Kojima, S, Sase, K, Miyata, T, Tomoike, H, Kawano, Y, Ogihara, T, Rakugi, H & Staessen, JA 2013, 'Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study', Pharmacogenomics, vol. 14, no. 14, pp. 1709-1721. https://doi.org/10.2217/PGS.13.161

@article{8bac11df503f442d9c3e61f113bd3c29,

title = "Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study",

abstract = "Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). Methods: We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10-4, we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine. Results: SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication. Conclusion: Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.",

author = "Yutaka Imai and Kei Kamide and Kei Asayama and Tomohiro Katsuya and Takayoshi Ohkubo and Takuo Hirose and Ryusuke Inoue and Hirohito Metoki and Masahiro Kikuya and Taku Obara and Hironori Hanada and Lutgarde Thijs and Tatiana Kuznetsova and Yuichi Noguchi and Ken Sugimoto and Mitsuru Ohishi and Shigeto Morimoto and Takeshi Nakahashi and Shin Takiuchi and Toshihiko Ishimitsu and Takuya Tsuchihashi and Masayoshi Soma and Jitsuo Higaki and Hideo Matsuura and Tatsuo Shinagawa and Toshiyuki Sasaguri and Tetsuro Miki and Kazuo Takeda and Kazuaki Shimamoto and Michio Ueno and Naohisa Hosomi and Jyouji Kato and Norio Komai and Shunichi Kojima and Kazuhiro Sase and Toshiyuki Miyata and Hitonobu Tomoike and Yuhei Kawano and Toshio Ogihara and Hiromi Rakugi and Staessen, {Jan A.}",

year = "2013",

month = nov,

doi = "10.2217/PGS.13.161",

language = "English",

volume = "14",

pages = "1709--1721",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "14",

}

TY - JOUR

T1 - Genome-wide response to antihypertensive medication using home blood pressure measurements

T2 - A pilot study nested within the HOMED-BP study

AU - Imai, Yutaka

AU - Kamide, Kei

AU - Asayama, Kei

AU - Katsuya, Tomohiro

AU - Ohkubo, Takayoshi

AU - Hirose, Takuo

AU - Inoue, Ryusuke

AU - Metoki, Hirohito

AU - Kikuya, Masahiro

AU - Obara, Taku

AU - Hanada, Hironori

AU - Thijs, Lutgarde

AU - Kuznetsova, Tatiana

AU - Noguchi, Yuichi

AU - Sugimoto, Ken

AU - Ohishi, Mitsuru

AU - Morimoto, Shigeto

AU - Nakahashi, Takeshi

AU - Takiuchi, Shin

AU - Ishimitsu, Toshihiko

AU - Tsuchihashi, Takuya

AU - Soma, Masayoshi

AU - Higaki, Jitsuo

AU - Matsuura, Hideo

AU - Shinagawa, Tatsuo

AU - Sasaguri, Toshiyuki

AU - Miki, Tetsuro

AU - Takeda, Kazuo

AU - Shimamoto, Kazuaki

AU - Ueno, Michio

AU - Hosomi, Naohisa

AU - Kato, Jyouji

AU - Komai, Norio

AU - Kojima, Shunichi

AU - Sase, Kazuhiro

AU - Miyata, Toshiyuki

AU - Tomoike, Hitonobu

AU - Kawano, Yuhei

AU - Ogihara, Toshio

AU - Rakugi, Hiromi

AU - Staessen, Jan A.

PY - 2013/11

Y1 - 2013/11

N2 - Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). Methods: We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10-4, we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine. Results: SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication. Conclusion: Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.

AB - Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). Methods: We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10-4, we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine. Results: SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication. Conclusion: Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=84893208653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893208653&partnerID=8YFLogxK

U2 - 10.2217/PGS.13.161

DO - 10.2217/PGS.13.161

M3 - Article

C2 - 24192120

AN - SCOPUS:84893208653

SN - 1462-2416

VL - 14

SP - 1709

EP - 1721

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 14

ER -

Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this